QMAC-dRAST S17 CLSI Antibiotic Panel Kit for dRAST, 10 Tests

Our dRAST test kit consists of Panel, Agarose, and Broth. The kit runs on the dRAST system and delivers MIC-based phenotypic susceptibility results directly from positive blood culture in as low as 4 hours. Gram-positive and Gram-negative panels using either CLSI or EUCAST recommended antimicrobials and breakpoints are available for dRAST.

Kit components

• QMAC-dRAST Panel: 96-well plate with panel of dried-down antibiotics at various concentrations
• QMAC-dRAST Agarose: Gel used for bacterial immobilization
• QMAC-dRAST Broth: Pipette tips and broth dispensed to enable bacterial growth

Antibiotic panel

• CLSI panel: 17 Gram-positive , 19 Gram-negative antibiotics with multiple concentrations
• EUCAST panel: 18 Gram-positive , 17 Gram-negative antibiotics with multiple concentrations

CLSI panel, Gram negative (QMdRASTN02)

CLSI panel, Gram positive (QMdRASTP02)

Workflow

Clinical workflow

Clinical evidence

dRAST provides susceptibility test results with greater reliability at enhanced speed.

Analysis of susceptibility results generated by conventional testing methods took an average of 64.5 hours while results from dRAST direct from positive blood cultures only took 14.3 hours.

Susceptibility result from dRAST is not only rapid but also reliable. Compared to Broth Micro-Dilution (BMD), the overall agreement for dRAST was 94.2% (49/52) and 98.5% (66/67) for patients with gram-positive and gram-negative bacteremia, respectively.

Kim et al., Journal of Medical Microbiology 2018; 67: 325-331

Rapid AST is critical for timely prescribing of optimal, targeted antimicrobials.

A prospective study demonstrated the superior impact of dRAST on the selection of optimal antimicrobial therapy for resistant strains compared to Gram staining or MALDI-TOF MS identification.

The proportion of optimal targeted treatment was similar between the Gram-staining and the MALDI-TOF MS groups. However, there was significant improvement for the dRAST group compared to the MALDI-TOF MS group. The dRAST group demonstrated a 32% higher rate of optimal, targeted antimicrobial therapy compared to MALDI-TOF and the rate of ineffective therapy was 26% lower.

The study demonstrated that result of rapid AST using dRAST contributes significantly more than that of bacterial ID to the administration of optimal targeted antimicrobial treatment.

Kim et al., Journal of Antimicrobial Chemotherapy, Volume 74, Issue 8, August 2019, Pages 2255–2260

Rapid AST by dRAST enables successful implementation of antimicrobial stewardship even in the treatment of bacteremia in the immunosuppressed patients.

Rapid AST by dRAST enables successful implementation of antimicrobial stewardship even for immunosuppressed patients with bacteremia as well as those with underlying hematological disorders.

Deploying dRAST into the diagnostic process allows more timely management of optimal, targeted treatment. In a recent study, time to initiation of optimal, targeted antimicrobials decreased by 14 hours in the dRAST group (39.0 hrs) compared to the conventional AST group (53.2 hrs).

In addition, the proportion of patients receiving optimal, targeted treatment at 48 hours from the first blood draw higher was higher in the dRAST group (66.1%) compared to the conventional AST group (48.3%). Also, the proportion of patients receiving broad-spectrum treatment at 48 hours was lower in the dRAST group (21.4%) compared to the conventional AST group (31.7%).

Kim et al., Clin Microbiol Infect. Volume 27, Issue 1, 2021,Pages 69-75

Documents

• Safety Data Sheet, Gram Negative kit (QMdRASTN02)
• Safety Data Sheet, Gram Positive kit (QMdRASTP02)